The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants in current and future COVID-19 vaccine trials. This... policy brief was developed by the WHO Access to COVID-19 Tools (ACT) Accelerator Ethics & Governance Working Group, to provide guidance for researchers, sponsors, regulators, research ethics committees, and policy-makers, on these and related issues.
more
Esta “Guía para la elaboración a nivel local de formulaciones recomendadas por la OMS para la desinfección de las manos”, está dividida en dos secciones específicas, relacionadas entre sí
The Seventy-fifth World Health Assembly through a decision on sustainable financing, adopted the recommendations of the Member States Working Group on Sustainable Financing, contained in Appendix 2 of the Working Group’s report to the Seventy-fifth World Health Assembly. As part of the recommendat...ions, the Secretariat was requested to “explore the feasibility of a replenishment mechanism to broaden further the financing base, in consultation with Member States and taking into consideration the Framework of Engagement with Non-State Actors; and to present a report that includes relevant options for Member States to consider, to the Seventy-sixth World Health Assembly, through the 152nd session of the Executive Board and the thirty-seventh meeting of the Programme, Budget and Administration Committee in January 2023” (paragraph 39(f) of Appendix 2 of the Working Group’s report). In response to this request, the Secretariat reviewed the feasibility of a WHO replenishment mechanism in line with the principles set out by the Working Group on Sustainable Financing. It consulted with Member States through the work of the Agile Member States Task Group on strengthening WHO’s budgetary, programmatic and financing governance and benchmarked a set of replenishment mechanisms within and beyond the global health arena. This report outlines the Secretariat’s review and proposals on key elements of a potential WHO replenishment mechanism.
more
19 August 2022. A monkeypox case investigation form (CIF) has been designed as a tool for Member States and researchers to conduct in-depth epidemiological investigation of suspected, probable and confirmed cases of monkeypox. This form allows to collect data prospectively or retrospectively for bot...h cases and their contacts. The full form is meant to serve as a tool for in-country use and the data are not required to be reported to WHO.
more
Adaptable guidance, tools, trainings, and advocacy materials are being developed to support countries in preparing for COVID-19 vaccination. Please visit this page regularly for updates.
Steps on how to safely collect oral swabs (saliva) from deceased patients suspected to be infected with Ebola: before entering patient’s room, how to put on and remove personal protective equipment (PPE), how to collect oral swab from deceased patient and how to prepare VTM collection tube for tra...nsport.
more
Des milliers de personnes meurent chaque jour des suites d’infections acquises au cours des procédures de soins.
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
Com o tema A equidade, o coração da saúde, este Plano busca catalisar esforços nos Estados Membros para reduzir as iniquidades em saúde dentro dos países e territórios e entre eles, a fim de melhorar os resultados em termos de saúde. O Plano identifica ações específicas para enfrentar a d...esigualdade em saúde, como as recomendadas pela Comissão sobre Equidade e Desigualdades em Saúde nas Américas, com a orientação da Comissão de Alto Nível para a Saúde Universal. Quatro temas transversais são centrais para o enfoque deste Plano para abordar os determinantes da saúde: a equidade, o gênero, a etnia e os direitos humanos.
more
The Country Readiness and Delivery(CRD) workstream which is part of the ACT Accelerator and is included in the SPRP– has developed a toolbox with guidance, tools and training.
Data received as of July 3, 2017 | WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2018
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...stance in adults, children and adolescents receiving dolutegravir-based ART.
This sentinel method is implemented complementary to WHO-recommended methods for estimating nationally representative levels of acquired HIV drug resistance.
more
“Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. Some of the vector control interventions deployed in complex emergencies and in response to natural disasters – namely insecticide-treated nets (ITNs) and indoo...r residual spraying (IRS) – have already met identified public health needs in more stable settings; other tools such as insecticide-treated tarpaulins have been specifically designed for this use case. Given the diverse mix of existing and potential new interventions and the considerable gaps in the associated evidence base, this PPC aims to clearly articulate the unmet public health needs for tools designed to control malaria transmission in complex emergencies and in response to natural disasters.
more
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
populations sous TAR. Bien que la résistance au DT...G ne soit pas apparue dans les populations naïves aux TAR incapables
de supprimer la charge virale dans les essais cliniques, certains éléments portent à croire que la résistance au
DTG peut émerger chez les personnes suivant des schémas thérapeutiques incluant le DTG. L’OMS recommande aux
pays qui étendent les TAR incluant le DTG d’accompagner ce déploiement d’une surveillance en routine de la pharmacorésistance
more
The WHO COVID-19 LENS (Living Evidence Synthesis) working group consolidated available evidence, based on rapid reviews of the literature and results of a living systematic review on pregnancy and COVID-19 (up to October 7, 2020), on potential mechanisms of vertical transmission of infectious pathog...ens, feasibility of vertical transmission of SARS-CoV-2, data related to interpretation of positive SARS-CoV-2 virologic and serologic neonatal tests, lessons from diagnosis of other congenital infections, and existing proposed definitions to classify timing of vertical transmission of SARS-CoV-2.
more